Skip to main content

Table 4 Multivariable logistic regression models of fatal outcomes (Death)

From: Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database

Variable

Number of cases

Adjusted OR (95%CI)

P

Gender

   

Female

1104

1.00 (Reference)

 

Male

1508

1.42 (1.15–1.76)

< 0.01

Age(years)

   

< 65

1036

1.00 (Reference)

 

≥ 65

1576

1.36 (1.10–1.69)

< 0.01

Weight (kg)

   

< 80

2000

1.00 (Reference)

 

80–100

496

0.62 (0.46–0.82)

< 0.01

> 100

116

0.90 (0.54–1.47)

0.66

Drug therapy

   

G treatment

734

1.00 (Reference)

 

AG treatment

1878

1.18 (0.94–1.49)

0.16

  1. Abbreviation OR: odds ratio; CI: confidence interval; G treatment, gemcitabine monotherapy; AG treatment, gemcitabine combined with albumin-bound paclitaxel; p < 0.05 were considered statistically significant
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us